Can Parkinson's disease be cured by stimulating neurogenesis?

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 978-980

  Foltynie, Thomas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLATELET DERIVED GROWTH FACTOR BB; ANTIPARKINSON AGENT; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB;

DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FUTUROLOGY; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBVENTRICULAR ZONE; TREATMENT RESPONSE; MALE;

ANTIPARKINSON AGENTS; HUMANS; MALE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 84924023996     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80822     Document Type: Review

References (20)

1. Nutt JG, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73.
2. Gill SS, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9(5):589-595.
3. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005;102(2):216-222.
4. Lang AE, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459-466.
5. Hovland DN Jr., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol. 2007;35(5 ):676-692.
6. Patel NK, Pavese N, Javed S, Hotton GR, Brooks DJ, Gill SS. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology. 2013;81(13):1176-1178.
7. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. ?-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Tr ansl Med. 2012;4(163):163ra156.
8. Funa K, et al. Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience. 1996;74(3):825-833.
9. Zachrisson O, et al. Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis. 2011;1(1):49-63.
10. Mo ore L, Bain JM, Loh JM, Levison SW. PDGFresponsive progenitors persist in the subventricular zone across the lifespan. ASN Neuro. 2014;6(2):65-81.
11. Mohapel P,Frielingsdorf H,Häggbla d J,Zachrisson O,Brundin P Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions Neuroscience. 2005 132 3): 767-776.
12. Paul G, et al. Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients. J Clin Invest. 2015;125(3):1339-1346.
13. Chen Y, Ai Y, Slevin JR, Maley BE, Gash DM. Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp Neurol. 2005;196(1):87-95.
14. Cabezas R, Avila MF, González J, El-BacháRS, Barreto GE. PDGF-BB protects mitochondria from Rotenone in T98G cells [published online ahead of print December 17, 2014]. Neurotox Res. doi:10.10 07/s12640-014-9509-5.
15. Funa K, Sasahara M. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system. J Neuroimmune Pharmacol. 2014;9(2):168-181.
16. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301.
17. Pakkenberg B, Møller A, Gundersen HJ, Mouritze n Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 1991;54(1 ):30-33.
18. Kordower JH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136(pt 8):2419-2431.
19. Athauda D, F oltynie T. The ongoing pursuit of neuroprotective therpaies in Parkinson disease. Nat Rev Neurol. 2015;11(1):25-40.
20. Luk KC, et al. Pathological ?-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949-953.